Anti–PD-L1–IFN-α–adjuvanted HBsAg vaccine overcomes HBV immune tolerance through targeting both DCs and macrophages
Chao-Yang Meng, Yong Liang, Longxin Xu, Hongjia Li, Jingya Guo, Hairong Xu, Fan Wang, Yang-Xin Fu, Hua Peng · 2025
Read Anti–PD-L1–IFN-α–adjuvanted HBsAg vaccine overcomes HBV immune tolerance through targeting both DCs and macrophages by Chao-Yang Meng, Yong Liang, Longxin Xu, Hongjia Li, Jingya Guo, Hairong Xu, Fan Wang, Yang-Xin Fu, Hua Peng (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12890514.txt.
Description
Meng and co-authors engineer in 2025 a fusion protein adjuvant that helps a hepatitis B vaccine break immune tolerance in mice. Standard surface antigen vaccines fail to wake T and B cells in chronic infection hosts. Their protein joins an anti PD-L1 arm with interferon alpha in one molecule.
Given with the vaccine under the skin, it boosted antigen uptake and maturation in both macrophage and dendritic cell groups in lymph nodes. Macrophages fired early B cell activation, while one dendritic subset primed killer T cells. Mice made neutralizing antibodies and specific killer cells, a functional cure without body wide toxicity. Effects needed both the targeting arm and interferon signaling.
Catalog record
| CREATOR | Chao-Yang Meng, Yong Liang, Longxin Xu, Hongjia Li, Jingya Guo, Hairong Xu, Fan Wang, Yang-Xin Fu, Hua Peng |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |